Meeting
2019 ASCO Annual Meeting
MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).
Authors
Meng XU WELLIVER
The Ohio State University, Columbus, OH
Meng XU WELLIVER , Brian Andrew Van Tine , Peter Houghton , Michelle A. Rudek , Raphael E. Pollock , John Michael Kane III, Gary K. Schwartz , Peixin Zhang , David G. Kirsch , Paul Wakely , Steve B. Jiang , Shahanawaz Jiwani , Alan D. Rogers , Dian Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03217266
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS11076)
DOI
10.1200/JCO.2019.37.15_suppl.TPS11076
Abstract #
TPS11076
Poster Bd #
398a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.
First Author: Meng Xu WELLIVER
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang
Poster
2020 ASCO Virtual Scientific Program
KRT‑232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD‑1/L1 immunotherapy.
First Author: Michael K.K. Wong
Poster
2011 ASCO Annual Meeting
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
First Author: O. L. Chinot